arrow
M

Michael C. Stauder

univ texas md anderso n canc ctr
H指数:27
被引数:3,156

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A phase Ib/II trial of neoadjuvant neratinib added to standard therapy in patients with HER2-positive or HR-positive/HER2-negative inflammatory breast cancer (including stage III and IV disease)

一项Ib/II期临床试验,研究在HER2阳性或HR阳性/HER2阴性炎性乳腺癌患者(包括III期和IV期疾病)中,将奈拉替尼加入标准疗法的新辅助治疗。

2025-10-140
OA
The impact of breast radiotherapy on the tumor genome and immune ecosystem

乳腺癌放射治疗对肿瘤基因组和免疫生态系统的影响

2025-05-010
OA
Development of a multi-institutional dataset to validate a novel inflammatory breast cancer diagnostic score

开发一个多机构数据集以验证一种新型炎性乳腺癌诊断评分

2025-03-310
PRE
PRECISE: Preoperative Radiation Therapy to Elicit Critical Immune Stimulating Effects-A Phase 2 Clinical Trial
2025-01-010
PRE
Development of a multi-institutional, photograph-rich clinical dataset to test and validate a novel inflammatory breast cancer (IBC) scoring system
2024-05-020
PRE
Prospective, early longitudinal assessment of lymphedema-related quality of life among patients with locally advanced breast cancer: The foundation for building a patient-centered screening program
BREAST
IF7.9
2023-04-014
OAAI
Prediction of breast cancer-related lymphedema by dermal backflow detected with near-infrared fluorescence lymphatic imaging

近红外荧光淋巴成像检测皮肤回流预测乳腺癌相关淋巴水肿

2022-07-1016
OAAI
Breast Radiation Therapy-Related Treatment Outcomes in Patients With or Without Germline Mutations on Multigene Panel Testing
2022-02-019
OAAI
Outcomes After Breast Radiation Therapy in a Diverse Patient Cohort With a Germline BRCA1/2 Mutation
2022-02-011
OAAI
Five-Year Longitudinal Analysis of Patient-Reported Outcomes and Cosmesis in a Randomized Trial of Conventionally Fractionated Versus Hypofractionated Whole-Breast Irradiation
2021-10-0115
OAAI
A pilot study to examine the feasibility of measuring CTC and inflammatory biomarker changes resulting from atorvastatin as adjuvant therapy in TNBC and TN-IBC patients with residual disease after neoadjuvant chemotherapy
2020-02-150
PRE